Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

CSF biomarkers predict a more malignant outcome in Alzheimer disease.

Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O.

Neurology. 2010 May 11;74(19):1531-7. doi: 10.1212/WNL.0b013e3181dd4dd8.

PMID:
20458070
2.

Specific estrogen sulfotransferase (SULT1E1) substrates and molecular imaging probe candidates.

Cole GB, Keum G, Liu J, Small GW, Satyamurthy N, Kepe V, Barrio JR.

Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6222-7. doi: 10.1073/pnas.0914904107. Epub 2010 Mar 19.

3.

High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types.

Villemagne VL, Ataka S, Mizuno T, Brooks WS, Wada Y, Kondo M, Jones G, Watanabe Y, Mulligan R, Nakagawa M, Miki T, Shimada H, O'Keefe GJ, Masters CL, Mori H, Rowe CC.

Arch Neurol. 2009 Dec;66(12):1537-44. doi: 10.1001/archneurol.2009.285.

PMID:
20008660
4.

Quantitative analysis of [18F]FDDNP PET using subcortical white matter as reference region.

Wong KP, Wardak M, Shao W, Dahlbom M, Kepe V, Liu J, Satyamurthy N, Small GW, Barrio JR, Huang SC.

Eur J Nucl Med Mol Imaging. 2010 Mar;37(3):575-88. doi: 10.1007/s00259-009-1293-8. Epub 2009 Oct 31.

5.

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative..

Ann Neurol. 2009 Apr;65(4):403-13. doi: 10.1002/ana.21610.

6.

Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly.

Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC, Holtzman DM.

Ann Neurol. 2009 Feb;65(2):176-83. doi: 10.1002/ana.21559.

7.

Biochemical markers in persons with preclinical familial Alzheimer disease.

Ringman JM, Younkin SG, Pratico D, Seltzer W, Cole GM, Geschwind DH, Rodriguez-Agudelo Y, Schaffer B, Fein J, Sokolow S, Rosario ER, Gylys KH, Varpetian A, Medina LD, Cummings JL.

Neurology. 2008 Jul 8;71(2):85-92. doi: 10.1212/01.wnl.0000303973.71803.81. Epub 2008 May 28.

PMID:
18509095
8.

PET of brain amyloid and tau in mild cognitive impairment.

Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, Lavretsky H, Burggren AC, Cole GM, Vinters HV, Thompson PM, Huang SC, Satyamurthy N, Phelps ME, Barrio JR.

N Engl J Med. 2006 Dec 21;355(25):2652-63.

9.

The A431E mutation in PSEN1 causing familial Alzheimer's disease originating in Jalisco State, Mexico: an additional fifteen families.

Murrell J, Ghetti B, Cochran E, Macias-Islas MA, Medina L, Varpetian A, Cummings JL, Mendez MF, Kawas C, Chui H, Ringman JM.

Neurogenetics. 2006 Nov;7(4):277-9. Epub 2006 Aug 5.

10.

The Thr354Ile substitution in PSEN1:: disease-causing mutation or polymorphism?

Lee P, Medina L, Ringman JM.

Neurology. 2006 Jun 27;66(12):1955-6. No abstract available.

PMID:
16801675
11.

Familial Alzheimer's disease presenilin 1 mutations cause alterations in the conformation of presenilin and interactions with amyloid precursor protein.

Berezovska O, Lleo A, Herl LD, Frosch MP, Stern EA, Bacskai BJ, Hyman BT.

J Neurosci. 2005 Mar 16;25(11):3009-17.

12.

Spanish and English Neuropsychological Assessment Scales (SENAS): further development and psychometric characteristics.

Mungas D, Reed BR, Crane PK, Haan MN, González H.

Psychol Assess. 2004 Dec;16(4):347-59.

PMID:
15584794
13.

Mutations in APP have independent effects on Abeta and CTFgamma generation.

Hecimovic S, Wang J, Dolios G, Martinez M, Wang R, Goate AM.

Neurobiol Dis. 2004 Nov;17(2):205-18.

PMID:
15474359
14.

APOE and other loci affect age-at-onset in Alzheimer's disease families with PS2 mutation.

Wijsman EM, Daw EW, Yu X, Steinbart EJ, Nochlin D, Bird TD, Schellenberg GD.

Am J Med Genet B Neuropsychiatr Genet. 2005 Jan 5;132B(1):14-20.

PMID:
15389756
15.

Female preclinical presenilin-1 mutation carriers unaware of their genetic status have higher levels of depression than their non-mutation carrying kin.

Ringman JM, Diaz-Olavarrieta C, Rodriguez Y, Chavez M, Paz F, Murrell J, Macias MA, Hill M, Kawas C.

J Neurol Neurosurg Psychiatry. 2004 Mar;75(3):500-2.

16.

Apolipoprotein Eepsilon4 modifies Alzheimer's disease onset in an E280A PS1 kindred.

Pastor P, Roe CM, Villegas A, Bedoya G, Chakraverty S, García G, Tirado V, Norton J, Ríos S, Martínez M, Kosik KS, Lopera F, Goate AM.

Ann Neurol. 2003 Aug;54(2):163-9.

PMID:
12891668
17.

Presenilin mutations line up along transmembrane alpha-helices.

Hardy J, Crook R.

Neurosci Lett. 2001 Jun 29;306(3):203-5.

PMID:
11406330
18.

Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma.

Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, Minthon L, Wallin A, Blennow K, Vanmechelen E.

Amyloid. 2000 Dec;7(4):245-58.

PMID:
11132093
19.

Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation.

Lopera F, Ardilla A, Martínez A, Madrigal L, Arango-Viana JC, Lemere CA, Arango-Lasprilla JC, Hincapíe L, Arcos-Burgos M, Ossa JE, Behrens IM, Norton J, Lendon C, Goate AM, Ruiz-Linares A, Rosselli M, Kosik KS.

JAMA. 1997 Mar 12;277(10):793-9.

PMID:
9052708

Supplemental Content

Support Center